A randomized, open-label, clinical trial examined the effects of canagliflozin on albuminuria and eGFR decline using an individual pre-intervention eGFR slope-Reference-Cited by-同舟云学术

A randomized, open-label, clinical trial examined the effects of canagliflozin on albuminuria and eGFR decline using an individual pre-intervention eGFR slope

Published:2024-08 Issue: Volume: Page:
ISSN:0085-2538
Container-title:Kidney International
language:en
Short-container-title:Kidney International

Author:

Miyamoto Satoshi^ORCID,Heerspink Hiddo J.L.^ORCID,de Zeeuw Dick,Sakamoto Kota,Yoshida Michihiro,Toyoda Masao,Suzuki Daisuke,Hatanaka Takashi,Nakamura Tohru,Kamei Shinji,Murao Satoshi,Hida Kazuyuki,Ando Shinichiro,Akai Hiroaki,Takahashi Yasushi,Kitada Munehiro,Sugano Hisashi,Nunoue Tomokazu,Nakamura Akihiko,Sasaki Motofumi,Nakatou Tatsuaki,Fujimoto Kei,Kawanami Daiji,Wada Takashi,Miyatake Nobuyuki,Kuramoto Hiromi,Shikata Kenichi

Funder

Mitsubishi Tanabe Pharma Corporation

Publisher

Elsevier BV

Reference23 articles.

1. GFR decline and subsequent risk of established kidney outcomes: a meta-analysis of 37 randomized controlled trials;Lambers Heerspink;Am J Kidney Dis,2014

2. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration;Levey;Am J Kidney Dis,2014

3. Effects of newer kidney protective agents on kidney endpoints provide implications for future clinical trials;Heerspink;Kidney Int,2023

4. Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in collaboration with the US Food and Drug Administration and European Medicines Agency;Levey;Am J Kidney Dis,2020

5. Uses of GFR and albuminuria level in acute and chronic kidney disease;Levey;N Engl J Med,2022